# YL202

Source: https://onco.cc/drugs/yl202/  
OnCo record `yl202` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

YL202 is an experimental antibody-drug conjugate (ADC) from MediLink Therapeutics (Suzhou) in phase 3 trials for non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and colorectal cancer, aimed at HER3.

## Summary

YL202 is an antibody-drug conjugate (ADC) developed by MediLink Therapeutics (Suzhou). Its target is HER3 (the sponsor names HER3). ClinicalTrials.gov describes the intervention as: YL202 will be intravenously infused over 60±10 min. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07416994 (Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer) and NCT07461454 (YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer), in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, colorectal cancer and cervical cancer. The largest, NCT07416994, plans to enrol 440 participants with primary completion expected 2028-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC)
- Mechanism: Antibody-drug conjugate (ADC) directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of YL202: https://clinicaltrials.gov/search?intr=YL202

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [HER3](https://onco.cc/targets/her3/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)
- trials: [A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC](https://onco.cc/trials/nct06439771/), [A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07169994/), [A Study of YL202 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07202364/), [A Study of YL202 in Selected Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06107686/), [Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07416994/), [YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer](https://onco.cc/trials/nct07461454/)

---
JSON: https://onco.cc/api/v1/entities/yl202.json